[{"data":1,"prerenderedAt":119},["ShallowReactive",2],{"topic-policy-access":3},{"articles":4,"guides":118},[5],{"id":6,"title":7,"author":8,"authorTitle":9,"body":10,"date":104,"description":105,"draft":106,"extension":107,"featured":106,"heroCredit":108,"heroImage":109,"meta":110,"navigation":111,"path":112,"readingTime":113,"seo":114,"stem":115,"topic":116,"__hash__":117},"articles\u002Farticles\u002Fwho-gets-to-be-a-patient.md","Who gets to be a patient?","Higher Place editors",null,{"type":11,"value":12,"toc":95},"minimark",[13,17,22,25,31,35,38,41,45,61,64,68,90],[14,15,16],"p",{},"Suppose the optimistic version comes true and one or more psychedelic therapies\nare approved for serious, hard-to-treat conditions. A quieter question\nimmediately follows the celebratory one: who, in practice, will actually be\nable to receive them?",[18,19,21],"h2",{"id":20},"a-labour-intensive-treatment-is-an-access-problem","A labour-intensive treatment is an access problem",[14,23,24],{},"These are not pills you collect from a pharmacy. The model under study\ninvolves trained clinicians, hours of preparation, a supervised dosing session\nthat can last most of a day, and integration over weeks. That is expensive and\nslow by design. Left to the market alone, a treatment with those properties\ntends to reach the affluent and well-connected first, and everyone else much\nlater, if at all.",[26,27,28],"blockquote",{},[14,29,30],{},"A therapy that only the comfortable can afford does not reduce suffering. It\nredistributes it upward.",[18,32,34],{"id":33},"the-pattern-is-already-visible","The pattern is already visible",[14,36,37],{},"This is not hypothetical. Oregon's regulated psilocybin services, open since\n2023, are paid for out of pocket, with a single supported session commonly\ncosting well over a thousand dollars, because the programme sits outside\nmedicine and no insurer covers it. Australia allowed authorised psychiatrists to\nprescribe psilocybin and MDMA from mid-2023, and the early reports were of a\nsmall number of providers charging fees in the tens of thousands of dollars.\nEsketamine, a nasal spray related to ketamine that was approved for depression\nin the United States in 2019, comes with clinic-supervised dosing and reached\npeople with good insurance first.",[14,39,40],{},"The research population tells the same story from the other end. A 2018 review\nof psychedelic trials found that more than four in five participants were\nwhite, which means the evidence base is thinnest for many of the communities\ncarrying the heaviest burden of untreated illness.",[18,42,44],{"id":43},"what-designing-for-access-looks-like","What designing for access looks like",[46,47,48,52,55,58],"ul",{},[49,50,51],"li",{},"Training pathways that do not restrict this work to a small, costly elite.",[49,53,54],{},"Coverage decisions that consider need, not only ability to pay.",[49,56,57],{},"Research populations that resemble the people who will eventually need care,\nso the evidence actually generalises to them.",[49,59,60],{},"Regulated routes that do not depend on living in the right state or province.\nCanada's Special Access Program, for instance, has allowed physicians to\nrequest psilocybin or MDMA for individual patients since 2022, but only case\nby case and only for those who find a willing prescriber.",[14,62,63],{},"The scientific question — does it work? — is being taken seriously. The\ndistributive question — for whom? — deserves the same seriousness, and it has\nto be asked now, while the answers can still be shaped.",[18,65,67],{"id":66},"sources-and-further-reading","Sources and further reading",[46,69,70,78,81,84,87],{},[49,71,72,73,77],{},"Michaels TI et al. \"Inclusion of people of color in psychedelic-assisted\npsychotherapy: a review of the literature.\" ",[74,75,76],"em",{},"BMC Psychiatry",", 2018.",[49,79,80],{},"Oregon Health Authority, Oregon Psilocybin Services.",[49,82,83],{},"Therapeutic Goods Administration (Australia), change to classification of\npsilocybin and MDMA, effective 1 July 2023.",[49,85,86],{},"Health Canada, Special Access Program: amendments to the Food and Drug\nRegulations, January 2022.",[49,88,89],{},"US FDA approval of esketamine (Spravato) for treatment-resistant depression,\nMarch 2019.",[14,91,92],{},[74,93,94],{},"This essay is general information, not medical advice. Access rules and costs\nchange frequently; check current sources for your jurisdiction.",{"title":96,"searchDepth":97,"depth":97,"links":98},"",3,[99,101,102,103],{"id":20,"depth":100,"text":21},2,{"id":33,"depth":100,"text":34},{"id":43,"depth":100,"text":44},{"id":66,"depth":100,"text":67},"2026-04-02","If psychedelic therapy becomes a real treatment, the next question is not whether it works but who will be able to reach it — and whether access will follow need or money.",false,"md","Higher Place — original artwork","\u002Fimg\u002Fheroes\u002Fpolicy-access.svg",{},true,"\u002Farticles\u002Fwho-gets-to-be-a-patient",7,{"title":7,"description":105},"articles\u002Fwho-gets-to-be-a-patient","policy-access","e0_CM4bTxw7BuLHdA0xZCe1ZMz6ClhvhqHwbkF2iTH0",[],1791168159480]